Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Sees Significant Growth in Short Interest

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) was the recipient of a large increase in short interest in December. As of December 15th, there was short interest totaling 13,528,238 shares, an increase of 36.9% from the November 30th total of 9,881,577 shares. Based on an average trading volume of 24,227,526 shares, the short-interest ratio is presently 0.6 days. Approximately 17.0% of the shares of the stock are short sold. Approximately 17.0% of the shares of the stock are short sold. Based on an average trading volume of 24,227,526 shares, the short-interest ratio is presently 0.6 days.

Aspire Biopharma Price Performance

Shares of ASBP stock opened at $0.11 on Tuesday. The business has a 50-day moving average price of $0.17 and a two-hundred day moving average price of $0.31. Aspire Biopharma has a 12-month low of $0.07 and a 12-month high of $15.80. The firm has a market cap of $11.61 million, a P/E ratio of -0.22 and a beta of 0.87.

Aspire Biopharma (NASDAQ:ASBP) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.04) earnings per share for the quarter. The company had revenue of $0.00 million during the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Aspire Biopharma in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

Hedge Funds Weigh In On Aspire Biopharma

Several institutional investors and hedge funds have recently made changes to their positions in the business. CIBC Bancorp USA Inc. bought a new stake in Aspire Biopharma in the third quarter worth $28,000. Jane Street Group LLC increased its holdings in shares of Aspire Biopharma by 625.8% in the second quarter. Jane Street Group LLC now owns 152,552 shares of the company’s stock worth $41,000 after buying an additional 131,533 shares during the period. Optivise Advisory Services LLC increased its holdings in shares of Aspire Biopharma by 120.9% in the second quarter. Optivise Advisory Services LLC now owns 235,106 shares of the company’s stock worth $63,000 after buying an additional 128,660 shares during the period. Crewe Advisors LLC lifted its stake in shares of Aspire Biopharma by 100.0% in the 2nd quarter. Crewe Advisors LLC now owns 626,854 shares of the company’s stock valued at $169,000 after acquiring an additional 313,427 shares during the last quarter. Finally, Procyon Advisors LLC boosted its holdings in Aspire Biopharma by 558.3% during the 2nd quarter. Procyon Advisors LLC now owns 648,411 shares of the company’s stock valued at $174,000 after acquiring an additional 549,911 shares during the period. Institutional investors own 19.17% of the company’s stock.

Aspire Biopharma Company Profile

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.